Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

Add Yahoo as a preferred source to see more of our stories on Google. A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in ...

UCSF researchers recently gave an overview of their latest work launching a new Institute for HIV Cure Research, funded by a $20 million grant from amfAR, the Foundation for AIDS Research. Cure ...

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

Harerimana Ismail of Uganda is a community health worker who checks on kids with HIV. He lost his salary after the Trump ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...